PI3K/AKT/mTOR通路
蛋白激酶B
医学
临床试验
癌症
替西罗莫司
子宫内膜癌
癌症研究
mTORC2型
生物信息学
肿瘤科
mTOR抑制剂的发现与发展
药理学
内科学
信号转导
生物
mTORC1型
生物化学
作者
Fabio Barra,Giulio Evangelisti,Lorenzo Ferro Desideri,Stefano Di Domenico,Domenico Ferraioli,Valerio Gaetano Vellone,Franco De Cian,Simone Ferrero
标识
DOI:10.1080/13543784.2018.1558202
摘要
Several new agents are under evaluation for treating patients with metastatic, recurrent, and persistent EC. Clinical trials investigating PI3K/AKT/mTOR inhibitors have yielded controversial results. In the near future, new studies with dual inhibitors or multi-pathways inhibitors as mono or combination therapies with conventional chemotherapy (CT) or other targeted drugs may provide more promising data. Moreover, the evaluation of new serum and histological biomarkers is an attractive strategy for patient selection.
科研通智能强力驱动
Strongly Powered by AbleSci AI